Document is current
Any future updates will be listed below
-
Authors
Elhage, Kareem G.
Davis, Mitchell S.
Hakimi, Marwa
Spencer, Riley K.
Jin, Joy Q.
Yeroushalmi, Samuel
Chung, Mimi
Bartholomew, Erin
Bhutani, Tina
Liao, Wilson
-
Funding
Funding for this research was provided by:
AbbVie
Castle Biosciences
CorEvitas
Dermavant
Galderma
Mindera
Pfizer
Novartis
Regeneron Pharmaceuticals
Arcutis
Boehringer Ingelheim
Bristol-Myers Squibb
Janssen Biotech
Leo
Lilly
Sun
UCB
Amgen
- License Information
-
More Information
Article History
Received: 6 September 2022
Revised: 16 November 2022
Accepted: 5 December 2022
First Online: 12 December 2022
Declarations
:
: Tina Bhutani is a principal investigator for trials sponsored by Abbvie, Castle, CorEvitas, Dermavant, Galderma, Mindera, and Pfizer. She has received research grant funding from Novartis and Regeneron. She has been an advisor for Abbvie, Arcutis, Boehringer-Ingelheim, Bristol Myers Squibb, Janssen, Leo, Lilly, Novartis, Pfizer, Sun, and UCB. Wilson Liao has received research grant funding from Abbvie, Amgen, Janssen, Leo, Novartis, Pfizer, Regeneron, and TRex Bio. The remaining authors have nothing to disclose.
: Not applicable.
